 | | Vol. 14.11 – 21 March, 2023 |
| |
|
|
| Researchers described the results of the first-in-human Phase I clinical trial investigating revumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukemia.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using single cell transcriptomics, scientists longitudinally profiled bone marrow and blood samples from patients with aplastic anemia undergoing allogeneic HSC transplantation with G-CSF–mobilized grafts.
[Science Immunology] |
|
|
|
| Investigators showed that in contrast to most cells that primarily utilize the proteasome to degrade misfolded proteins, HSCs preferentially traffic misfolded proteins to aggresomes in a Bag3-dependent manner and depend on aggrephagy, a selective form of autophagy, to maintain proteostasis in vivo.
[Cell Stem Cell] |
|
|
|
| Researchers revealed a Plek2/Akt complex that drove cell proliferation and could be targeted by a class of antiproliferative compounds for myeloproliferative neoplasm therapy.
[Journal Of Clinical Investigation] |
|
|
|
| Scientists found a conserved epitranscriptomic program that steers SF3B1 levels to counteract leukemogenesis. Their analysis of human and murine pre-leukemic myelodysplastic syndrome (MDS) cells revealed regulation of SF3B1 protein abundance, which affected MDS-to-leukemia progression in vivo.
[Molecular Cell] |
|
|
|
| Through gene expression profiling, investigators found HES6 as an abundant cofactor expressed at gene level during human erythropoiesis.
[Nucleic Acids Research] |
|
|
|
| Scientists used an in vitro differentiation system and RNA-sequencing to compare monocyte-derived dendritic cells from Langerhans cell histiocytosis patients to those derived from healthy controls or patients with Crohn’s disease, a non-histiocytic inflammatory disease.
[Haematologica] |
|
|
|
| Researchers studied the switch/sugar non-fermenting subunit BCL7A, which was found to be recurrently mutated in lymphomas, but whose role in acute myeloid malignancies is currently unknown.
[Biomarker Research] |
| |
|
|
| Clinical effect of donor-derived natural killer cell infusion after HLA-haploidentical hematopoietic cell transplantation (HCT) was evaluated in high-risk myeloid malignancy in Phase II, randomized trial.
[Leukemia] |
|
|
|
|
| The authors review the observational and mechanistic studies describing the connection between clonal hematopoiesis (CH) and pathological immune dysfunction, as well as the effects of CH-associated genetic alterations on the function of myeloid and lymphoid cells.
[Nature Reviews Immunology] |
|
|
|
|
| Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a Phase II clinical study of patients with DBA.
[Disc Medicine, Inc.] |
|
|
|
|
| April 23 – 26, 2023
Paris, France |
|
|
|
|
|
| | University of Florida – Gainesville, Florida, United States |
|
|
|
| | Columbia University – New York City, New York, United States |
|
|
|
| | King’s College London – Strand, England, United Kingdom |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
